0.35 (-%)
As of Nov 21, 2024
Source:
Organovo Holdings, Inc. is a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (“IBD”), including ulcerative colitis (“UC”), based on demonstration of clinical promise in three-dimensional (“3D”) human tissues as well as strong preclinical data. FXR is a mediator of gastrointestinal and liver diseases. FXR agonism has been tested in a variety of preclinical models of IBD.
Country | United States |
Headquarters | san diego, california |
Phone Number | 858-224-1000 |
Industry | manufacturing |
CEO | Keith Murphy |
Website | www.organovo.com |